Notice Information
Notice Title
National Registry of Robotically Assisted Surgery
Notice Description
The contract will initially be delivered for NHS-funded care in England for a period of 3 years, at a maximum total budget of up to PS1,300,320 including VAT, PS1,083,600 excluding VAT. Bids exceeding this limit may be rejected. There is the potential to extend this contract for up to 24 months via either a funded extension or the method stated in section 4.2 of Annex A. All pricing submissions must be in regard to this 'core' value, and not inclusive of any extension costs or aspirational intent costs, i.e. Please only submit a cost schedule up to the maximum core value of PS1,300,320 including VAT, PS1,083,600 excluding VAT. The maximum budget 'core' value of PS1,300,320 including VAT, PS1,083,600 excluding VAT excludes the potential two year extension and aspirational intent as described in section 14.4 of Annex A - Service Specification. Please note, there is no commitment by the Authority at this stage to include any aspirational intent measures. Taking the total of this aspirational intent into account, as well as the possibility that a contract extension may be offered for an additional two years, the potential ceiling value is PS10,800,808 GBP including VAT, PS8,640,646.40 excluding VAT. The registry should aim to address, where possible and as a priority, the recommendations and requirements of the NICE early evaluation assessment (EVA) and is expected to support the acquisition of relevant metrics. NICE EVA orthopaedics - https://www.nice.org.uk/guidance/htg743/resources/evidence-generation-plan-for-robotassisted-surgery-for-orthopaedic-procedures-15306435181/chapter/1-Purpose-of-this-document and NICE EVA soft tissue - https://www.nice.org.uk/guidance/htg742 The registry will continue to evolve in line with the uptake of robotic surgery working with Medicines and Healthcare products Regulatory Agency (MHRA), NHSE, National Equipment Tracking and Information System (NETIS) and NICE to ensure evidence generation, availability of data for analysis to highlight variations in care and poor outcomes including health inequities The aims of the national robotically assisted surgical registry are to: *Improve patient safety by tracking short- and long-term results of robotically assisted surgery *Capture key quality metrics aligned with the requirements of the NICE EVA recommendations (see section 9.3) *Support the standardisation of practice *Identify variation in surgical outcomes across hospitals *Provide outcome evidence to inform clinical guidelines, commissioning, and regulatory decisions *Facilitate research and innovation conducted by others in robotic surgical technologies and techniques *Understand the current provision and the equity of access to help inform future strategic decisions. *Make available, near real time data for authorities to evaluate the effectiveness of robotically assisted surgery compared with conventional techniques *Maintain close alignment with relevant NICE national guidance and quality standards throughout the establishment of the registry (see section 9.1 and appendix 1) *Provide timely and high-quality data analysis that compares providers of healthcare *Be clinically led *Link data where feasible and of value at an individual patient level to other relevant national datasets either from the outset or in the future, and plan for these linkages from the inception of the contract *Use robust methodological and statistical techniques (see section 6.2.2) *Provide outputs tailored to a variety of different audiences Provide results in a timely, accessible and meaningful manner minimising the reporting delay and providing continual access to each stakeholder for their own data *Develop and maintain strong engagement with local clinicians, networks, commissioners, patients and their families and carers and charity and community support groups to drive improvements in services The project requirements are*: *A registry that captures prospective key data about robotically assisted surgery. This registry should be delivered by 2029 therefore, before the end of year three of the contract *The provision of information to address, where possible, the evidence gaps highlighted by the NICE medical technologies advisory committee concerning promising health technologies that have the potential to address national unmet need (see: Committee discussion) *To, during the first three years, design a self-sustaining style funding model. The funder and commissioner should be involved in all discussions with final sign-off approval. It is anticipated that at the end of the 3-year contract term the funding should switch from a publicly funded to a self-sustaining funding model. Given the pump priming publicly funded start up to this project, the expectation is that the current funders will be involved at all stages of the self-sustaining future model and be integrally involved as a primary stakeholder in the governance and oversight *With the set up and implementation of a self-sustaining financial model, the registry should consider a mechanism to enable the flow of data to robotic manufacturers named in the NICE EVA (or other safety programmes) and who contribute to the funding of the registry when the self-sustaining model is developed. Information for manufacturers may potentially include data for product and system improvement, safety and post-market surveillance, benchmarking and performance feedback, value demonstration, collaborative research and development. The supplier should avoid providing information to manufacturers that supports commercial messaging or market advantage and be confined to information relating to service user outcomes *That the registry's design and governance arrangements consider the remit and existing data holdings of other similar registries and data collections, ensuring interoperability where appropriate and avoiding duplication of data collection, analytical outputs, or reporting functions *At the conclusion of the three-year contract term, the strategic intention is for the registry to mature into a continuous, prospective data collection underpinned by a sustainable, self- funding model. This transition must not dilute or displace the required system-level oversight. HQIP and NHSE will therefore remain central and non-negotiable partners within the governance framework for the registry throughout the contract and into any subsequent phase *The supplier will be required, to commit to this governance structure, including the roles of HQIP and NHSE, and to demonstrate how their proposed operating model will support effective accountability, assurance and long-term sustainability *The development of this registry including data platforms and tools within this contract are initially a proof of concept and future delivery arrangements are currently unknown. If a self-funding model is agreed and developed as defined in this section (3.2), it will form part of the contractual deliverable requirements, specifically adhering to clause 20, intellectual property, of the terms and conditions. Migration to a definitive platform under future commissioning arrangements may be necessary and the future portability of a technical solution must be considered and be freely available to transition between any outgoing and incoming providers, along with all other foreground IPR rights contained within clause 20 of the terms and conditions *There may be a clinical need to evolve and expand the metrics to capture additional metrics outside of the NICE EVA requirements. The supplier will need to closely collaborate with NICE to consider changes to metrics and mutually agreeable metric modifications. *The registry will continue to evolve in line with the uptake of robotic surgery working with MHRA, NHSE, NETIS and NICE to ensure evidence generation, availability of data for analysis to highlight variations in care and poor outcomes including health inequities *Please refer to section 13.2 for further potential additional requirements for this contract.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-0661d2
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/019354-2026
- Current Stage
- Tender
- All Stages
- Tender
Procurement Classification
- Notice Type
- UK4 - Tender Notice
- Procurement Type
- Standard
- Procurement Category
- Services
- Procurement Method
- Open
- Procurement Method Details
- Open procedure
- Tender Suitability
- SME, VCSE
- Awardee Scale
- Not specified
Common Procurement Vocabulary (CPV)
- CPV Divisions
85 - Health and social work services
-
- CPV Codes
85100000 - Health services
Notice Value(s)
- Tender Value
- £8,640,646 £1M-£10M
- Lots Value
- £8,640,646 £1M-£10M
- Awards Value
- Not specified
- Contracts Value
- Not specified
Notice Dates
- Publication Date
- 4 Mar 20261 weeks ago
- Submission Deadline
- 13 Apr 20265 weeks to go
- Future Notice Date
- Not specified
- Award Date
- Not specified
- Contract Period
- 30 Sep 2026 - 30 Sep 2029 3-4 years
- Recurrence
- Not specified
Notice Status
- Tender Status
- Active
- Lots Status
- Active
- Awards Status
- Not Specified
- Contracts Status
- Not Specified
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- HEALTHCARE QUALITY IMPROVEMENT PARTNERSHIP LTD
- Contact Name
- Available with D3 Tenders Premium →
- Contact Email
- Available with D3 Tenders Premium →
- Contact Phone
- Available with D3 Tenders Premium →
Buyer Location
- Locality
- LONDON
- Postcode
- EC1V 2NX
- Post Town
- Central London
- Country
- England
-
- Major Region (ITL 1)
- TLI London
- Basic Region (ITL 2)
- TLI4 Inner London - East
- Small Region (ITL 3)
- TLI43 Haringey and Islington
- Delivery Location
- Not specified
-
- Local Authority
- Islington
- Electoral Ward
- Bunhill
- Westminster Constituency
- Islington South and Finsbury
Further Information
Notice Documents
-
https://www.find-tender.service.gov.uk/Notice/019354-2026
4th March 2026 - Tender notice on Find a Tender
Notice URLs
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-0661d2-2026-03-04T10:44:23Z",
"date": "2026-03-04T10:44:23Z",
"ocid": "ocds-h6vhtk-0661d2",
"initiationType": "tender",
"parties": [
{
"id": "GB-PPON-PVVQ-6113-CJWD",
"name": "Healthcare Quality Improvement Partnership Ltd",
"identifier": {
"scheme": "GB-PPON",
"id": "PVVQ-6113-CJWD"
},
"address": {
"streetAddress": "128 City Road",
"locality": "London",
"postalCode": "EC1V 2NX",
"country": "GB",
"countryName": "United Kingdom",
"region": "UKI43"
},
"contactPoint": {
"email": "procurement@hqip.org.uk",
"telephone": "0000000000"
},
"roles": [
"buyer"
],
"details": {
"classifications": [
{
"id": "publicAuthoritySubCentralGovernment",
"scheme": "UK_CA_TYPE",
"description": "Public authority - sub-central government"
}
]
}
}
],
"buyer": {
"id": "GB-PPON-PVVQ-6113-CJWD",
"name": "Healthcare Quality Improvement Partnership Ltd"
},
"tender": {
"id": "ocds-h6vhtk-0661d2",
"legalBasis": {
"id": "2023/54",
"scheme": "UKPGA",
"uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
},
"title": "National Registry of Robotically Assisted Surgery",
"description": "The contract will initially be delivered for NHS-funded care in England for a period of 3 years, at a maximum total budget of up to PS1,300,320 including VAT, PS1,083,600 excluding VAT. Bids exceeding this limit may be rejected. There is the potential to extend this contract for up to 24 months via either a funded extension or the method stated in section 4.2 of Annex A. All pricing submissions must be in regard to this 'core' value, and not inclusive of any extension costs or aspirational intent costs, i.e. Please only submit a cost schedule up to the maximum core value of PS1,300,320 including VAT, PS1,083,600 excluding VAT. The maximum budget 'core' value of PS1,300,320 including VAT, PS1,083,600 excluding VAT excludes the potential two year extension and aspirational intent as described in section 14.4 of Annex A - Service Specification. Please note, there is no commitment by the Authority at this stage to include any aspirational intent measures. Taking the total of this aspirational intent into account, as well as the possibility that a contract extension may be offered for an additional two years, the potential ceiling value is PS10,800,808 GBP including VAT, PS8,640,646.40 excluding VAT. The registry should aim to address, where possible and as a priority, the recommendations and requirements of the NICE early evaluation assessment (EVA) and is expected to support the acquisition of relevant metrics. NICE EVA orthopaedics - https://www.nice.org.uk/guidance/htg743/resources/evidence-generation-plan-for-robotassisted-surgery-for-orthopaedic-procedures-15306435181/chapter/1-Purpose-of-this-document and NICE EVA soft tissue - https://www.nice.org.uk/guidance/htg742 The registry will continue to evolve in line with the uptake of robotic surgery working with Medicines and Healthcare products Regulatory Agency (MHRA), NHSE, National Equipment Tracking and Information System (NETIS) and NICE to ensure evidence generation, availability of data for analysis to highlight variations in care and poor outcomes including health inequities The aims of the national robotically assisted surgical registry are to: *Improve patient safety by tracking short- and long-term results of robotically assisted surgery *Capture key quality metrics aligned with the requirements of the NICE EVA recommendations (see section 9.3) *Support the standardisation of practice *Identify variation in surgical outcomes across hospitals *Provide outcome evidence to inform clinical guidelines, commissioning, and regulatory decisions *Facilitate research and innovation conducted by others in robotic surgical technologies and techniques *Understand the current provision and the equity of access to help inform future strategic decisions. *Make available, near real time data for authorities to evaluate the effectiveness of robotically assisted surgery compared with conventional techniques *Maintain close alignment with relevant NICE national guidance and quality standards throughout the establishment of the registry (see section 9.1 and appendix 1) *Provide timely and high-quality data analysis that compares providers of healthcare *Be clinically led *Link data where feasible and of value at an individual patient level to other relevant national datasets either from the outset or in the future, and plan for these linkages from the inception of the contract *Use robust methodological and statistical techniques (see section 6.2.2) *Provide outputs tailored to a variety of different audiences Provide results in a timely, accessible and meaningful manner minimising the reporting delay and providing continual access to each stakeholder for their own data *Develop and maintain strong engagement with local clinicians, networks, commissioners, patients and their families and carers and charity and community support groups to drive improvements in services The project requirements are*: *A registry that captures prospective key data about robotically assisted surgery. This registry should be delivered by 2029 therefore, before the end of year three of the contract *The provision of information to address, where possible, the evidence gaps highlighted by the NICE medical technologies advisory committee concerning promising health technologies that have the potential to address national unmet need (see: Committee discussion) *To, during the first three years, design a self-sustaining style funding model. The funder and commissioner should be involved in all discussions with final sign-off approval. It is anticipated that at the end of the 3-year contract term the funding should switch from a publicly funded to a self-sustaining funding model. Given the pump priming publicly funded start up to this project, the expectation is that the current funders will be involved at all stages of the self-sustaining future model and be integrally involved as a primary stakeholder in the governance and oversight *With the set up and implementation of a self-sustaining financial model, the registry should consider a mechanism to enable the flow of data to robotic manufacturers named in the NICE EVA (or other safety programmes) and who contribute to the funding of the registry when the self-sustaining model is developed. Information for manufacturers may potentially include data for product and system improvement, safety and post-market surveillance, benchmarking and performance feedback, value demonstration, collaborative research and development. The supplier should avoid providing information to manufacturers that supports commercial messaging or market advantage and be confined to information relating to service user outcomes *That the registry's design and governance arrangements consider the remit and existing data holdings of other similar registries and data collections, ensuring interoperability where appropriate and avoiding duplication of data collection, analytical outputs, or reporting functions *At the conclusion of the three-year contract term, the strategic intention is for the registry to mature into a continuous, prospective data collection underpinned by a sustainable, self- funding model. This transition must not dilute or displace the required system-level oversight. HQIP and NHSE will therefore remain central and non-negotiable partners within the governance framework for the registry throughout the contract and into any subsequent phase *The supplier will be required, to commit to this governance structure, including the roles of HQIP and NHSE, and to demonstrate how their proposed operating model will support effective accountability, assurance and long-term sustainability *The development of this registry including data platforms and tools within this contract are initially a proof of concept and future delivery arrangements are currently unknown. If a self-funding model is agreed and developed as defined in this section (3.2), it will form part of the contractual deliverable requirements, specifically adhering to clause 20, intellectual property, of the terms and conditions. Migration to a definitive platform under future commissioning arrangements may be necessary and the future portability of a technical solution must be considered and be freely available to transition between any outgoing and incoming providers, along with all other foreground IPR rights contained within clause 20 of the terms and conditions *There may be a clinical need to evolve and expand the metrics to capture additional metrics outside of the NICE EVA requirements. The supplier will need to closely collaborate with NICE to consider changes to metrics and mutually agreeable metric modifications. *The registry will continue to evolve in line with the uptake of robotic surgery working with MHRA, NHSE, NETIS and NICE to ensure evidence generation, availability of data for analysis to highlight variations in care and poor outcomes including health inequities *Please refer to section 13.2 for further potential additional requirements for this contract.",
"status": "active",
"items": [
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UK",
"country": "GB",
"countryName": "United Kingdom"
}
],
"relatedLot": "1"
}
],
"value": {
"amountGross": 10800808,
"amount": 8640646.4,
"currency": "GBP"
},
"procurementMethod": "open",
"procurementMethodDetails": "Open procedure",
"mainProcurementCategory": "services",
"aboveThreshold": true,
"submissionMethodDetails": "https://www.delta-esourcing.com/respond/J3EC5N6DAH",
"submissionTerms": {
"electronicSubmissionPolicy": "allowed",
"languages": [
"en"
]
},
"tenderPeriod": {
"endDate": "2026-04-13T12:00:00+01:00"
},
"enquiryPeriod": {
"endDate": "2026-03-30T12:00:00+01:00"
},
"awardPeriod": {
"endDate": "2026-08-01T23:59:59+01:00"
},
"lots": [
{
"id": "1",
"status": "active",
"value": {
"amountGross": 10800808,
"amount": 8640646.4,
"currency": "GBP"
},
"awardCriteria": {
"criteria": [
{
"type": "quality",
"name": "1. Leadership",
"description": "500 word count",
"numbers": [
{
"number": 6,
"weight": "percentageExact"
}
]
},
{
"type": "quality",
"name": "2. Engaging And Involving Patients, Carers And The Public",
"description": "500 word count",
"numbers": [
{
"number": 8,
"weight": "percentageExact"
}
]
},
{
"type": "quality",
"name": "3. Stimulating Healthcare Quality Improvement",
"description": "750 word count",
"numbers": [
{
"number": 4,
"weight": "percentageExact"
}
]
},
{
"type": "quality",
"name": "4. Healthcare Provider Engagement, Participation and Support",
"description": "500 word count",
"numbers": [
{
"number": 5,
"weight": "percentageExact"
}
]
},
{
"type": "quality",
"name": "5. Data Acquisition Strategy and Burden",
"description": "750 word count",
"numbers": [
{
"number": 14,
"weight": "percentageExact"
}
]
},
{
"type": "quality",
"name": "6. Information Governance",
"description": "250 word count",
"numbers": [
{
"number": 4,
"weight": "percentageExact"
}
]
},
{
"type": "quality",
"name": "7. Data Quality and Analysis",
"description": "750 word count",
"numbers": [
{
"number": 12,
"weight": "percentageExact"
}
]
},
{
"type": "quality",
"name": "8. Uses of the Data",
"description": "750 word count",
"numbers": [
{
"number": 12,
"weight": "percentageExact"
}
]
},
{
"type": "quality",
"name": "9. Programme Governance and Delivery Plan",
"description": "750 word count",
"numbers": [
{
"number": 14,
"weight": "percentageExact"
}
]
},
{
"type": "quality",
"name": "10. Risk Management",
"description": "250 word count",
"numbers": [
{
"number": 6,
"weight": "percentageExact"
}
]
},
{
"type": "price",
"name": "11. Cost & Allocation of Budget",
"description": "250 word count",
"numbers": [
{
"number": 5,
"weight": "percentageExact"
}
]
},
{
"type": "quality",
"name": "12. Social Value",
"description": "500 word count",
"numbers": [
{
"number": 10,
"weight": "percentageExact"
}
]
}
]
},
"suitability": {
"sme": true,
"vcse": true
},
"contractPeriod": {
"startDate": "2026-10-01T00:00:00+01:00",
"endDate": "2029-09-30T23:59:59+01:00",
"maxExtentDate": "2031-09-30T23:59:59+01:00"
},
"hasRenewal": true,
"renewal": {
"description": "Up to 24 months"
}
}
],
"documents": [
{
"id": "conflictOfInterest",
"documentType": "conflictOfInterest",
"description": "Not published"
},
{
"id": "A-12857",
"documentType": "biddingDocuments",
"url": "https://www.find-tender.service.gov.uk/Notice/Attachment/A-12857",
"format": "application/vnd.openxmlformats-officedocument.wordprocessingml.document"
},
{
"id": "A-12858",
"documentType": "biddingDocuments",
"url": "https://www.find-tender.service.gov.uk/Notice/Attachment/A-12858",
"format": "application/vnd.openxmlformats-officedocument.wordprocessingml.document"
},
{
"id": "019354-2026",
"documentType": "tenderNotice",
"noticeType": "UK4",
"description": "Tender notice on Find a Tender",
"url": "https://www.find-tender.service.gov.uk/Notice/019354-2026",
"datePublished": "2026-03-04T10:44:23Z",
"format": "text/html"
}
],
"contractTerms": {
"financialTerms": "As per terms"
},
"riskDetails": "Full details of the aspirational intent and its mechanisms for invoking as well as potential maximum value are listed in Annex A - Service Specification. The below is a summary of the potential measures that may be invoked in order to reduce the risk of service delivery and are at the funders discretion. Bidders are advised to review the service specification, in particular, section 13.2 - Aspirational Intent, where the full description, nature, maximum value and mechanisms for invoking these measures are detailed. All figures below are inclusive of VAT 1. Up to 24-month extension that mirrors the NCAPOP headline contract - Up to PS840,000 plus a pro-rata of any costs invoked under aspirational intent as defined in the sections below 2. Transitioning to different models of data collection - Up to PS600,000 3. Inclusion of privately funded care - Up to PS600,000 4. Additional, associated or enhanced delivery of any aspect of the project - Up to PS1,200,000 5. Quality improvement initiatives either related to or linked with he project including the addition of surgeon level outliers - Up to PS500,000 6. Inclusion of additional national or international funders - Up to PS935,340 7. Changes in line with national policy - Up to PS1,200,000 8. Development of PROMs and PREM - Up to PS1,200,000 9. Inclusion of reporting and tracking against innovative surgical techniques - Up to PS1,200,000 10. Development costs for inclusion of additional or international funders - Up to PS144,000"
},
"language": "en"
}